摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-甲基-5-三氟甲基-1H-苯并咪唑 | 6742-82-1

中文名称
2-甲基-5-三氟甲基-1H-苯并咪唑
中文别名
——
英文名称
2-methyl-5-(trifluoromethyl)-1H-benzo[d]imidazole
英文别名
2-Methyl-5-trifluormethyl-benzimidazol;2-methyl-6-(trifluoromethyl)-1H-benzimidazole
2-甲基-5-三氟甲基-1H-苯并咪唑化学式
CAS
6742-82-1
化学式
C9H7F3N2
mdl
MFCD00526217
分子量
200.163
InChiKey
MXJRRPABGUWERH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    14
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.222
  • 拓扑面积:
    28.7
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2933990090

SDS

SDS:9718891906626c5c5f2ab68bde397ec0
查看
2-甲基-6-(三甲基)-1H-苯并咪唑MSDS英文版

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] USE OF BENZIMIDAZOLE-PROLINE DERIVATIVES<br/>[FR] UTILISATION DE DÉRIVÉS DE BENZIMIDAZOLE-PROLINE
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:WO2015083094A1
    公开(公告)日:2015-06-11
    The present invention relates to compounds of the formula (I), wherein Ar1 and Ar2 are as described in the description and to their use as pharmaceuticals for the treatment of sundown syndrome. The invention also relates to the preparation of such compounds and of pharmaceutically acceptable salts thereof.
    本发明涉及式(I)的化合物,其中Ar1和Ar2如描述中所述,并且它们作为治疗日落综合征的药物的用途,该发明还涉及制备这种化合物及其药用盐的方法。
  • Indium-mediated one-pot benzimidazole synthesis from 2-nitroanilines or 1,2-dinitroarenes with orthoesters
    作者:Jaeho Kim、Jihye Kim、Hyunseung Lee、Byung Min Lee、Byeong Hyo Kim
    DOI:10.1016/j.tet.2011.08.017
    日期:2011.10
    One-pot reduction-triggered heterocyclizations from 2-nitroanilines or 1,2-dinitroarenes to benzimidazoles were investigated in this study. In the presence of indium/AcOH in ethyl acetate at reflux, reaction of 2-nitroanilines or 1,2-dinitroarenes with R–C(OMe)3 (R=Me, Ph) produced excellent yields of the corresponding benzimidazoles within 30 min to 6 h depending on the substituents of the starting
    在此研究中,研究了从2-硝基苯胺或1,2-二硝基芳烃苯并咪唑的一锅还原触发的杂环化反应。在乙酸乙酯中存在/ AcOH的条件下,回流时,2-硝基苯胺或1,2-二硝基芳烃与RC(OMe)3(R = Me,Ph)的反应在30分钟内可得到优异的相应苯并咪唑收率。 6小时取决于起始材料的取代基。在类似的反应条件下,与1,2-二硝基芳烃苯并咪唑介导的2-硝基苯胺苯并咪唑的杂环化反应更快,并且产率更高。
  • ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF
    申请人:Meng Charles Q.
    公开号:US20140142114A1
    公开(公告)日:2014-05-22
    The present invention relates to novel anthelmintic compounds of formula (I) below: wherein Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicyclic carbocyclic or a bicyclic heterocyclic group and the other of Y or Z is alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, heterocyclyl or heteroaryl, and variables X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 and X 8 are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.
    本发明涉及以下式(I)的新型驱虫化合物: 其中 Y和Z分别是双环碳环或双环杂环基团,或者Y或Z中的一个是双环碳环或双环杂环基团,另一个是烷基,烯基,炔基,环烷基,苯基,杂环基或杂芳基,以及变量X 1 ,X 2 ,X 3 ,X 4 ,X 5 ,X 6 ,X 7 和X 8 如本文所定义。本发明还提供了包含本发明的驱虫化合物的兽药组合物,以及它们用于治疗和预防动物寄生虫感染的用途。
  • 4-(Benzoimidazol-2-yl)-thiazole Compounds and Related Aza Derivatives
    申请人:Actelion Pharmaceuticals Ltd.
    公开号:US20140371204A1
    公开(公告)日:2014-12-18
    The invention relates to compounds of Formula (I) wherein ring A, X, (R 1 ) n , R 2 , R 3 , R 4 , R 4′ , R 5 , n, and p are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the CXCR3 receptor.
    本发明涉及式(I)化合物,其中环A、X、(R1)n、R2、R3、R4、R4′、R5、n和p如描述中所述;涉及药用可接受的盐,以及将此类化合物用作药物,尤其是用作CXCR3受体的调节剂。
  • [EN] PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT<br/>[FR] DÉRIVÉS DE PIPÉRAZINE ET LEUR UTILISATION EN TANT QUE MÉDICAMENT
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2015055698A1
    公开(公告)日:2015-04-23
    The present inventions relate to substituted piperazine derivatives of general formula (I) and to the manufacture of said compounds, pharmaceutical compositions comprising a compound according to general formula (I), and the use of said compounds for the treatment of various medical conditions related to glycine transporter-1 (GlyT1).
    这些发明涉及一般式(I)的取代哌嗪生物,以及制备该化合物、包含符合一般式(I)的化合物的药物组合物,以及利用该化合物治疗与甘酸转运蛋白-1(GlyT1)相关的各种医疗状况。
查看更多